Acute Cellular Rejection and Humoral Sensitization in Lung Transplant Recipients

ABSTRACT

Despite the recent development of many new immunosuppressive agents for use in transplantation, acute cellular and humoral rejection represent extremely prevalent and serious complications after lung transplantation. Acute cellular rejection, defined as perivascular or bronchiolar mononuclear inflammation, affects over 50% of lung transplant recipients within the first year. Furthermore, the frequency and severity of acute rejections are the most important risk factors for the subsequent development of bronchiolitis obliterans syndrome (BOS), a condition of progressive airflow obstruction that severely limits survival after lung transplantation. Treatment options for cellular rejection include high-dose methylprednisolone, antithymocyte globulin, or alemtuzumab. Emerging evidence also suggests that humoral rejection occurs in lung transplantation, characterized by local complement activation or the presence of antibody to donor human leukocyte antigens and is associated with an increased risk for BOS. Treatment options for humoral rejection include intravenous immunoglobulin, plasmapheresis, or rituximab. Herein, we review the clinical presentation, diagnosis, mechanisms, and treatment of cellular and humoral rejection after lung transplantation.

KEYWORDS

Lung transplantation - acute rejection - humoral rejection - antibody-mediated rejection

REFERENCES

• 1 Trulock E P, Christie J D, Edwards L B et al.. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007.  J Heart Lung Transplant. 2007;  26 782-795
• 2 Sharples L D, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications.  J Heart Lung Transplant. 2002;  21 271-281
• 3 Snyder L D, Palmer S M. Immune mechanisms of lung allograft rejection.  Semin Respir Crit Care Med. 2006;  27 534-543
• 4 Colvin R B, Smith R N. Antibody-mediated organ-allograft rejection.  Nat Rev Immunol. 2005;  5 807-817
• 5 De Vito Dabbs A, Hoffman L A, Iacono A T, Zullo T G, McCurry K R, Dauber J H. Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation?.  Heart Lung. 2004;  33 372-380
• 6 Van Muylem A, Mélot C, Antoine M, Knoop C, Estenne M. Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation.  Thorax. 1997;  52 643-647
• 7 Gotway M B, Dawn S K, Sellami D et al.. Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis.  Radiology. 2001;  221 207-212
• 8 Shitrit D, Izbicki G, Fink G et al.. Late postoperative pleural effusion following lung transplantation: characteristics and clinical implications.  Eur J Cardiothorac Surg. 2003;  23 494-496
• 9 Stewart S, Fishbein M C, Snell G I et al.. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.  J Heart Lung Transplant. 2007;  26 1229-1242
• 10 Hopkins P M, Aboyoun C L, Chhajed P N et al.. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients.  J Heart Lung Transplant. 2002;  21 1062-1067
• 11 Trulock E P, Ettinger N A, Brunt E M, Pasque M K, Kaiser L R, Cooper J D. The role of transbronchial lung biopsy in the treatment of lung transplant recipients: an analysis of 200 consecutive procedures.  Chest. 1992;  102 1049-1054
• 12 Chakinala M M, Ritter J, Gage B F et al.. Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation.  J Heart Lung Transplant. 2004;  23 1396-1404
• 13 Reynaud-Gaubert M, Thomas P, Gregoire R et al.. Clinical utility of bronchoalveolar lavage cell phenotype analyses in the postoperative monitoring of lung transplant recipients.  Eur J Cardiothorac Surg. 2002;  21 60-66
• 14 De Soyza A, Fisher A J, Small T, Corris P A. Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation.  Am J Respir Crit Care Med. 2001;  164 1209-1212
• 15 Silkoff P E, Caramori M, Tremblay L et al.. Exhaled nitric oxide in human lung transplantation: a noninvasive marker of acute rejection.  Am J Respir Crit Care Med. 1998;  157(6 Pt 1) 1822-1828
• 16 Kowalski R J, Post D R, Mannon R B et al.. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay.  Transplantation. 2006;  82 663-668
• 17 Bhorade S M, Janata K, Vigneswaran W T, Alex C G, Garrity E R. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection.  J Heart Lung Transplant. 2008;  27 990-994
• 18 Huang Y, Nizami Nazih Zuhdi I. Correlation of Cylex ImmuKnow assay with lung allograft biopsy [abstract].  J Heart Lung Transplant. 2007;  26 S175
• 19 Yousem S A, Martin T, Paradis I L, Keenan R, Griffith B P. Can immunohistological analysis of transbronchial biopsy specimens predict responder status in early acute rejection of lung allografts?.  Hum Pathol. 1994;  25 525-529
• 20 Reams B D, Musselwhite L W, Zaas D W et al.. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation.  Am J Transplant. 2007;  7 2802-2808
• 21 Colombat M, Groussard O, Lautrette A et al.. Analysis of the different histologic lesions observed in transbronchial biopsy for the diagnosis of acute rejection: clinicopathologic correlations during the first 6 months after lung transplantation.  Hum Pathol. 2005;  36 387-394
• 22 Chakinala M M, Ritter J, Gage B F et al.. Reliability for grading acute rejection and airway inflammation after lung transplantation.  J Heart Lung Transplant. 2005;  24 652-657
• 23 Stephenson A, Flint J, English J et al.. Interpretation of transbronchial lung biopsies from lung transplant recipients: inter- and intraobserver agreement.  Can Respir J. 2005;  12 75-77
• 24 Burton C M, Iversen M, Scheike T, Carlsen J, Andersen C B. Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies.  Transplantation. 2008;  85 547-553
• 25 DeVito Dabbs A, Hoffman L A, Iacono A T et al.. Pattern and predictors of early rejection after lung transplantation.  Am J Crit Care. 2003;  12 497-507
• 26 Hachem R R, Khalifah A P, Chakinala M M et al.. The significance of a single episode of minimal acute rejection after lung transplantation.  Transplantation. 2005;  80 1406-1413
• 27 Kim D W, Dacic S, Iacono A, Grgurich W, Yousem S A. Significance of a solitary perivascular mononuclear infiltrate in lung allograft recipients with mild acute cellular rejection.  J Heart Lung Transplant. 2005;  24 152-155
• 28 Glanville A R, Aboyoun C L, Havryk A, Plit M, Rainer S, Malouf M A. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation.  Am J Respir Crit Care Med. 2008;  177 1033-1040
• 29 Scholma J, Slebos D J, Boezen H M et al.. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation.  Am J Respir Crit Care Med. 2000;  162 2221-2225
• 30 Schulman L L, Weinberg A D, McGregor C, Galantowicz M E, Suciu-Foca N M, Itescu S. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation.  Am J Respir Crit Care Med. 1998;  157(6 Pt 1) 1833-1837
• 31 Quantz M A, Bennett L E, Meyer D M, Novick R J. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations.  J Heart Lung Transplant. 2000;  19 473-479
• 32 Treede H, Klepetko W, Reichenspurner H Munich and Vienna Lung Transplant Group et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols.  J Heart Lung Transplant. 2001;  20 511-517
• 33 Hachem R R, Yusen R D, Chakinala M M et al.. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation.  J Heart Lung Transplant. 2007;  26 1012-1018
• 34 Kumar D, Erdman D, Keshavjee S et al.. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant.  Am J Transplant. 2005;  5 2031-2036
• 35 Garantziotis S, Howell D N, McAdams H P, Davis R D, Henshaw N G, Palmer S M. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome.  Chest. 2001;  119 1277-1280
• 36 Zheng H X, Burckart G J, McCurry K et al.. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation.  J Heart Lung Transplant. 2004;  23 541-546
• 37 Zheng H X, Zeevi A, McCurry K et al.. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients.  Transpl Immunol. 2005;  14 37-42
• 38 Palmer S M, Burch L H, Trindade A J et al.. Innate immunity influences long-term outcomes after human lung transplant.  Am J Respir Crit Care Med. 2005;  171 780-785
• 39 Palmer S M, Klimecki W, Yu L et al.. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14.  Am J Transplant. 2007;  7 693-699
• 40 Ibrahim J E, Sweet S C, Flippin M et al.. Rejection is reduced in thoracic organ recipients when transplanted in the first year of life.  J Heart Lung Transplant. 2002;  21 311-318
• 41 Scott J P, Whitehead B, de Leval M et al.. Paediatric incidence of acute rejection and obliterative bronchiolitis: a comparison with adults.  Transpl Int. 1994;  7(Suppl 1) S404-S406
• 42 Mahidhara R, Bastani S, Ross D J et al.. Lung transplantation in older patients?.  J Thorac Cardiovasc Surg. 2008;  135 412-420
• 43 Ruiz R, Kunitake H, Wilkinson A H et al.. Long-term analysis of combined liver and kidney transplantation at a single center.  Arch Surg. 2006;  141 735-741 discussion 741-742
• 44 Pinderski L J, Kirklin J K, McGiffin D et al.. Multi-organ transplantation: is there a protective effect against acute and chronic rejection?.  J Heart Lung Transplant. 2005;  24 1828-1833
• 45 Keenan R J, Bruzzone P, Paradis I L et al.. Similarity of pulmonary rejection patterns among heart-lung and double-lung transplant recipients.  Transplantation. 1991;  51 176-180
• 46 Lau C L, Palmer S M, D'Amico T A, Tapson V F, Davis R D. Lung transplantation at Duke University Medical Center.  Clin Transpl. 1998;  327-340
• 47 Vitulo P, Oggionni T, Cascina A et al.. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation.  J Heart Lung Transplant. 2002;  21 435-439
• 48 Sarahrudi K, Estenne M, Corris P et al.. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection.  J Thorac Cardiovasc Surg. 2004;  127 1126-1132
• 49 Shennib H, Massard G, Reynaud M, Noirclerc M. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.  J Heart Lung Transplant. 1994;  13 514-519
• 50 Keenan R J, Iacono A, Dauber J H et al.. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients.  J Thorac Cardiovasc Surg. 1997;  113 335-340 discussion 340-341
• 51 Dall'Amico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection.  Transfus Apher Sci. 2002;  26 197-204
• 52 Valentine V G, Robbins R C, Wehner J H, Patel H R, Berry G J, Theodore J. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts.  Chest. 1996;  109 1184-1189
• 53 Appel III J Z, Hartwig M G, Davis R D, Reinsmoen N L. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens.  Hum Immunol. 2005;  66 378-386
• 54 Appel III J Z, Hartwig M G, Cantu III E, Palmer S M, Reinsmoen N L, Davis R D. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies.  Transplantation. 2006;  81 1049-1057
• 55 Taylor C J, Smith S I, Morgan C H et al.. Selective omission of the donor cross-match before renal transplantation: efficacy, safety and effects on cold storage time.  Transplantation. 2000;  69 719-723
• 56 Girnita A L, McCurry K R, Iacono A T et al.. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection.  J Heart Lung Transplant. 2004;  23 1135-1141
• 57 Palmer S M, Davis R D, Hadjiliadis D et al.. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome.  Transplantation. 2002;  74 799-804
• 58 Hadjiliadis D, Chaparro C, Reinsmoen N L et al.. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study.  J Heart Lung Transplant. 2005;  24(7, Suppl) S249-S254
• 59 Burlingham W J, Love R B, Jankowska-Gan E et al.. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants.  J Clin Invest. 2007;  117 3498-3506
• 60 Goers T A, Ramachandran S, Aloush A, Trulock E, Patterson G A, Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection.  J Immunol. 2008;  180 4487-4494
• 61 Magro C M, Klinger D M, Adams P W et al.. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related.  Am J Transplant. 2003;  3 1264-1272
• 62 Badesch D B, Zamora M, Fullerton D et al.. Pulmonary capillaritis: a possible histologic form of acute pulmonary allograft rejection.  J Heart Lung Transplant. 1998;  17 415-422
• 63 Ionescu D N, Girnita A L, Zeevi A et al.. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody.  Transpl Immunol. 2005;  15 63-68
• 64 Miller G G, Destarac L, Zeevi A et al.. Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid.  Am J Transplant. 2004;  4 1323-1330
• 65 Magro C M, Abbas A E, Seilstad K, Pope-Harman A L, Nadasdy T, Ross Jr P. C3d and the septal microvasculature as a predictor of chronic lung allograft dysfunction.  Hum Immunol. 2006;  67 274-283
• 66 Westall G P, Snell G I, McLean C, Kotsimbos T, Williams T, Magro C. C3d and C4d deposition early after lung transplantation.  J Heart Lung Transplant. 2008;  27 722-728
• 67 Wallace W D, Reed E F, Ross D, Lassman C R, Fishbein M C. C4d staining of pulmonary allograft biopsies: an immunoperoxidase study.  J Heart Lung Transplant. 2005;  24 1565-1570
• 68 Astor T L, Weill D, Cool C, Teitelbaum I, Schwarz M I, Zamora M R. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function.  J Heart Lung Transplant. 2005;  24 2091-2097
• 69 Vo A A, Lukovsky M, Toyoda M et al.. Rituximab and intravenous immune globulin for desensitization during renal transplantation.  N Engl J Med. 2008;  359 242-251